Published Date: 04 Jul 2026
Traumatic brain injury is bidirectionally associated with the incidence of stroke, dementia, epilepsy, and Parkinson’s disease, a retrospective study shows.
Read Full NewsOcular motor cranial neuropathy is associated with an increased risk for Parkinson’s disease, a new study shows.
A large database study found overall 5- and 10-year improvement in pediatric cancer survival, but some cancers lag others, and demographic factors seem to influence trends.
Workforce projections show an uneven distribution of rheumatologists in the US, with notable shortages in nonmetropolitan areas and certain states and districts.
A phase 2 trial assesses fixed-duration epcoritamab monotherapy as first-line therapy for frail older adults with newly diagnosed anthracycline-ineligible large B-cell lymphoma.
All adults aged 65-74 with a chronic respiratory condition or a weakened immune system will be offered the RSV vaccine from September, NHS England has confirmed.
Emerging evidence suggests coffee influences gut microbiota through bioactive compounds beyond caffeine, with potential effects on digestive and metabolic health.
CAR T-cell therapy is expected to expand quickly across autoimmune skin diseases following an anticipated regulatory approval that might come as soon as this year.
1.
FDA Approves New Bladder Cancer First-Line Standard of Care.
2.
AI-based breast cancer risk technology receives FDA breakthrough device designation
3.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
4.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
5.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
1.
The Capmist DM: A Revolutionary Way to Combat Dry Mouth
2.
Unlocking the Mystery of Ovarian Cancer Staging
3.
Understanding the HAS-BLED Score: What It Is and Why It Matters
4.
Precision Cancer Risk Mitigation Strategies
5.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
5.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation